---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Phase of product development"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Phase of product development. Topics: Regulatory status: Under review; NDA accepted July 2026, PDUFA target action date April 2027; Launch: Anticipated in 2027; Investigational status and approval uncertainty; Content of the NDA; 20 further topics. 24 evidence topics quoted from 21 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Regulatory status: Under review; NDA accepted July 2026, PDUFA target action date April 2027

> “Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027”
> “The company’s New Drug Application (NDA) for deucrictibant IR for the on-demand treatment of HAE attacks is under review by the U.S. Food and Drug Administration”
> “(FDA), with the Prescription Drug User Fee Act (PDUFA) action date set for April 23, 2027.”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

> “A New Drug Application (NDA) for deucrictibant IR for the on-demand treatment of HAE attacks is currently under review with the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of April 23, 2027.”

Source: [Pharvaris RAPIDe-3 Lancet publication press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/phase-3-study-results-highlighting-deucrictibants-rapid-and)

> “In July 2026, the U.S. Food and Drug Administration (FDA) accepted to review the Company’s New Drug Application (NDA) for deucrictibant IR for the on-demand treatment of HAE attacks, with the Prescription Drug User Fee Act (PDUFA) action date set for April 23, 2027.”

Source: [Pharvaris Form 6-K, second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526345702/phvs-ex99_1.htm)

> “July 6, 2026”
> “today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand treatment (ODT) of Hereditary Angioedema (HAE) attacks. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of April 23, 2027.”

Source: [Pharvaris NDA acceptance press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-announces-fda-acceptance-new-drug-application)

<a id="topic-2.1.1-2"></a>

### Launch: Anticipated in 2027

> “The increase in general and administrative expenses is primarily due to increases in commercial personnel, professional, and other expenses, supporting a potential launch of IR in 2027.”
> “We expect to recognize revenues from sales of deucrictibant IR in 2027, if it is approved for sale in the United States by the FDA.”

Source: [Pharvaris Form 6-K, third quarter 2026 MD&A (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_2.htm)

<a id="topic-2.1.1-3"></a>

### Investigational status and approval uncertainty

> “Clinical development timelines and associated costs may vary significantly and FDA approval of deucrictibant IR for the treatment of on-demand attacks in 2027 is uncertain.”

Source: [Pharvaris Form 6-K, third quarter 2026 MD&A (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_2.htm)

> “We do not have any drugs that have received regulatory approval and may never be able to develop marketable products.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.1-4"></a>

### Content of the NDA

> “Pharvaris’ NDA details a comprehensive clinical development program for deucrictibant IR, including data from the treatment of over 1,300 HAE attacks.”

Source: [Pharvaris NDA acceptance press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-announces-fda-acceptance-new-drug-application)

<a id="topic-2.1.1-5"></a>

### European Medicines Agency marketing authorization application

> “In July 2026, the European Medicines Agency (EMA) validated the marketing authorization application (MAA) for deucrictibant IR and began its formal review of the MAA under the centralized procedure.”

Source: [Pharvaris Form 6-K, second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526345702/phvs-ex99_1.htm)

> “The marketing authorization application (MAA) for deucrictibant IR is under formal review by the European Medicines Agency (EMA) under the centralized procedure.”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.1.1-6"></a>

### NDA submission timing, May 2026, superseded in July 2026

> “Submission of New Drug Application (NDA) of deucrictibant immediate release (IR) capsule for the on-demand treatment of HAE attacks remains on-track for 1H2026.”
> “Data from the pivotal, randomized, placebo-controlled Phase 3 study, RAPIDe-3, and the long-term extension study, RAPIDe-2, will serve as the basis for the NDA of deucrictibant IR, which is on-track for submission to the U.S. Food and Drug Administration (FDA) in the first half of 2026.”

Source: [Pharvaris Form 6-K, first quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526219372/phvs-ex99_1.htm)

<a id="topic-2.1.1-7"></a>

### NDA submission timing, April 2026, superseded in July 2026

> “Timeline for submission of NDA dossier of deucrictibant IR for on-demand treatment of HAE attacks remains on-track in 1H2026”
> “Data from RAPIDe-3 and RAPIDe-2 will serve as the basis for the NDA of deucrictibant, which is on-track to be submitted in the first half of 2026.”

Source: [Pharvaris Form 6-K, fourth quarter and full year 2025 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000012/phvs-ex99_1.htm)

> “Pharvaris plans to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in the first half of 2026 for the on-demand treatment of acute attacks of HAE.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.1-8"></a>

### NDA submission timing, January 2026, superseded in July 2026

> “Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE attacks ongoing; timeline remains on-track for filing in 1H2026”
> “The data from RAPIDe-3 and RAPIDe-2 will serve as the basis for marketing authorization applications, which are planned to be filed starting in the first half of 2026.”

Source: [Pharvaris 2026 strategic priorities press release (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526009705/phvs-ex99_1.htm)

<a id="topic-2.1.1-9"></a>

### NDA submission timing, December 2025, superseded in July 2026

> “The data from Pharvaris’ first pivotal Phase 3 study will serve as the basis for marketing authorization applications, which are planned to be filed starting in the first half of 2026.”
> “Pharvaris remains on track to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in the first half of 2026 for the on-demand treatment of acute attacks of HAE.”

Source: [Pharvaris RAPIDe-3 topline press release (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000119312525305951/d69798dex991.htm)

<a id="topic-2.1.1-10"></a>

### NDA submission timing, July 2025, superseded in July 2026

> “Company expects to submit deucrictibant IR capsule NDA to the U.S. FDA for the on-demand treatment of HAE attacks in 1H2026”

Source: [Pharvaris RAPIDe-3 topline timing update press release (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000119312525157363/d17337dex991.htm)

<a id="topic-2.1.1-11"></a>

### RAPIDe-3 topline timing, January 2025, superseded in July 2025

> “Enrollment in RAPIDe-3, the pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, continuing as planned; topline data anticipated in 1Q2026”

Source: [Pharvaris 2025 strategic priorities press release (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000095017025004542/phvs-ex99_1.htm)

<a id="topic-2.1.1-12"></a>

### Development history: duration of the development program

> “After 10 years of dedicated effort by the team at Pharvaris, this FDA acceptance of deucrictibant IR’s NDA represents a major milestone in our journey to develop a differentiated therapy with the potential to improve the standard of care for people living with HAE,”

Source: [Pharvaris NDA acceptance press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-announces-fda-acceptance-new-drug-application)

<a id="topic-2.1.1-13"></a>

### Development history: phase 1 studies and the RAPIDe-1 phase 2 trial

> “To date we have data from preclinical studies, Phase 1 clinical studies in healthy volunteers, and Phase 2 studies in people living with HAE of deucrictibant for both treatment and prophylaxis of HAE attacks, and a Phase 3 study in people living with HAE of deucrictibant for the treatment of HAE attacks.”
> “We commenced RAPIDe-1 in February 2021 and reported positive topline Phase 2 data in December 2022.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.1-14"></a>

### Development history: end-of-phase 2 meeting with the FDA

> “An end-of-Phase 2 meeting with the agency occurred to align on key elements of RAPIDe-3 global Phase 3 study of deucrictibant immediate-release capsules for the on-demand treatment of HAE”

Source: [Pharvaris corporate presentation, January 2024 (2024)](https://www.sec.gov/Archives/edgar/data/1830487/000095017024002680/phvs-ex99_2.htm)

<a id="topic-2.1.1-15"></a>

### Development history: RAPIDe-3 initiation, enrollment, and topline results

> “Following the readout of RAPIDe-2, we initiated RAPIDe-3, a global, pivotal Phase 3, placebo-controlled study to evaluate deucrictibant IR capsule (20 mg) for the on-demand treatment of attacks in people 12 years and older with HAE, in March 2024 and reported topline data in December 2025.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “reached target enrollment in March 2025; the study continues to assess HAE attacks in enrolled participants.”

Source: [Pharvaris Form 6-K, second quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000095017025107316/phvs-ex99_1.htm)

> “Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025”

Source: [Pharvaris RAPIDe-3 topline timing update press release (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000119312525157363/d17337dex991.htm)

> “Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal”
> “ZUG, Switzerland, December 3, 2025”

Source: [Pharvaris RAPIDe-3 topline press release (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000119312525305951/d69798dex991.htm)

> “RAPIDe-3 study results highlighting deucrictibant’s rapid and sustained efficacy in treating HAE attacks published in The Lancet.”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.1.1-16"></a>

### Development history: RAPIDe-2 open-label extension

> “In addition, we are also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “An open-label extension study of deucrictibant IR for the on-demand treatment of HAE attacks, RAPIDe-2 (NCT05396105), is ongoing.”

Source: [Pharvaris RAPIDe-3 Lancet publication press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/phase-3-study-results-highlighting-deucrictibants-rapid-and)

<a id="topic-2.1.1-17"></a>

### Development history: CHAPTER-1, CHAPTER-3, and CHAPTER-4 prophylaxis trials of deucrictibant

> “We commenced CHAPTER-1 in November 2021 using twice-daily dosing of deucrictibant IR capsules as a proof-of-concept for once-daily deucrictibant XR tablets, and announced positive topline data in December 2023.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “CHAPTER-3 (NCT06669754) met the primary endpoint and all secondary efficacy endpoints with statistical significance.”
> “Treatment with deucrictibant XR in participants with all types of HAE reduced the mean monthly attack rate by 83% (p<0.0001)”
> “Filing of U.S. NDA of deucrictibant for the prophylaxis of AE-BK attacks anticipated 1H2027.”
> “The data from CHAPTER-3, CHAPTER-4 (NCT06679881), and part 1 of CREAATE will serve as the basis for marketing authorization applications, which are planned to be submitted starting in the first half of 2027.”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.1.1-18"></a>

### Development history: CREAATE in acquired angioedema due to C1 inhibitor deficiency

> “In October 2025, we initiated CREAATE, a global, pivotal Phase 3 study to assess the efficacy and safety of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks.”
> “In part 2, participants treat two attacks in a cross-over fashion, one attack with deucrictibant IR capsule (20 mg) and one with placebo, to evaluate deucrictibant IR as an on-demand treatment of AAE-C1INH attacks.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “Topline data from part 1 of CREAATE (NCT07266805) expected in 1Q2027.”
> “Enrollment in part 2 of CREAATE progressing as planned.”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.1.1-19"></a>

### FDA clinical hold, August 2022, and its lifts in June 2023 and January 2024

> “the U.S. Food and Drug Administration (FDA) verbally informed Pharvaris that, based on its review of nonclinical data, the agency is placing a clinical hold on the clinical trials of PHA121 in the U.S. under two Pharvaris Investigational New Drug (IND) applications for the treatment of HAE.”

Source: [Pharvaris clinical hold press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022029851/phvs-ex991_6.htm)

> “FDA has subsequently agreed to partially lift the clinical hold on RAPIDe-1 trial and allow 2 remaining U.S. participants in RAPIDe-1 to complete treatment of a final HAE attack per protocol.”

Source: [Maurer et al. (2023b)](https://ir.pharvaris.com/static-files/39663775-647d-44c4-8870-da48e883078f)

> “The agency requested that Pharvaris conduct an additional long-term rodent toxicology study and update the Investigator’s Brochure”
> “In June 2023, FDA removed the clinical hold on on-demand trials”

Source: [Pharvaris corporate presentation, January 2024 (2024)](https://www.sec.gov/Archives/edgar/data/1830487/000095017024002680/phvs-ex99_2.htm)

> “Findings were observed in the repeat-dose rat data package that were considered not to be related to bradykinin B2 receptor antagonism.”
> “Following review of data from a preplanned interim analysis of the study, the FDA lifted the clinical hold on the IND application for deucrictibant for the on-demand treatment of HAE in June 2023. In January 2024, the FDA lifted the clinical hold on the IND application for deucrictibant for the prophylactic treatment of HAE attacks following review of the full data set from the completed 26-week rodent toxicology study.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.1-20"></a>

### FDA thorough QT study waivers

> “Following review of preclinical and clinical data, the U.S. Food and Drug Administration (FDA) has accepted Pharvaris’ TQT study waiver requests. These waivers apply to the prophylactic program (IND153097) for deucrictibant extended-release formulation and the on-demand program (IND155872) for deucrictibant immediate-release formulation.”

Source: [Pharvaris Form 6-K, first quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000095017025070308/phvs-ex99_1.htm)

<a id="topic-2.1.1-21"></a>

### FDA orphan drug designation

| Field | Quoted record |
| --- | --- |
| Generic name | “deucrictibant” |
| Date designated | “03/18/2022” |
| Orphan designation | “Treatment of bradykinin-mediated angioedema (hereditary or acquired)” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “Pharvaris GmbH” |

Source: [FDA Orphan Drug Designations and Approvals (2022)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=809521)

> “On March 18, 2022, the FDA granted orphan drug designation to PHA121 (deucrictibant), the active ingredient in our IR and XR product candidates for treatment of bradykinin-mediated angioedema.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.1-22"></a>

### Orphan designations in the European Union and Switzerland

> “This medicine was designated as an orphan medicine for the treatment of bradykinin-mediated angioedema in the European Union on 25 March 2025.”

Source: [EMA orphan designation EU/3/25/3040 (2025)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3040)

| Field | Quoted record |
| --- | --- |
| Active substance | “deucrictibant monohydrate” |
| Intended use | “Treatment of bradykinin-mediated angioedema” |
| EU designation number | “EU/3/25/3040” |
| Date of designation | “25/03/2025” |
| Sponsor | “Pharvaris Netherlands B.V.” |

Source: [EMA orphan designation EU/3/25/3040 (2025)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3040)

> “Deucrictibant has been granted orphan drug designation for the treatment of bradykinin-mediated angioedema by the U.S. Food and Drug Administration, the European Commission, and Swissmedic.”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.1.1-23"></a>

### EU paediatric investigation plan, agreed October 2023 and modified January 2025

| Field | Quoted record |
| --- | --- |
| Decision | “P/0411/2023 of 25 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for deucrictibant” |
| Waiver | “the paediatric population from birth to less than 2 years of age” |
| Indication targeted by the plan | “Treatment of and prevention of hereditary angioedema (HAE) attacks in paediatric patients from 2 years to less than 18 years of age.” |
| Study in children under 12 years | “Open-label, sequential two-part study to assess pharmacokinetics, efficacy, and safety of deucrictibant (PHA-022121) for the treatment (Part 1) and prevention (Part 2) of attacks in paediatric patients from 2 years to less than 12 years and adolescents from 12 years to less than 18 years of age weighing less than 40 kg with hereditary angioedema” |
| Deferral | “Deferral for one or more measures contained in the paediatric investigation plan: Yes” |
| Date of completion | “Date of completion of the paediatric investigation plan: By January 2030” |

Source: [EMA paediatric investigation plan decision P/0411/2023 (2023)](https://www.ema.europa.eu/en/documents/pip-decision/p-0411-2023-ema-decision-25-october-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-deucrictibant-emea-003090-pip02-22_en.pdf)

> “PM: decision on the application for modification of an agreed PIP”
> “28/01/2025”

Source: [EMA paediatric investigation plan modification EMA/PE/0000227462 (2025)](https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000227462)

<a id="topic-2.1.1-24"></a>

### FDA expedited program designations

No evidence found.

<a id="topic-2.1.1-25"></a>

### Patent protection

> “As of December 31, 2025, we own five U.S. patents and 150 national/regional patents, including in Australia, China, India, Indonesia, Japan, Mexico, South Korea, France, Germany, Italy, Netherlands, Spain and United Kingdom, that expire on November 23, 2038 or later”
> “Two national/regional patents and 9 of our pending applications contain claims directed to the use of deucrictibant in on-demand treatment of HAE and in prophylaxis for HAE, and accordingly extend the patent applications to methods of use of the IR and XR product candidates.”
> “53 granted patents, including in China, France, Germany, Italy, Netherlands, Spain and United Kingdom, and 18 of our pending patent applications, including an U.S. application, contain claims directed to the formulation of our IR product candidate.”
> “In the future, if and when our product candidates receive approval from the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents we may obtain in the future covering deucrictibant, depending upon the length of the clinical trials for each product and other factors.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
